AIM: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection. METHODS:Two hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS: The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002). CONCLUSIONS: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea.
RCT Entities:
AIM: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection. METHODS: Two hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS: The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002). CONCLUSIONS: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea.
Authors: B C Wong; S D Xiao; F L Hu; S C Qian; N X Huang; Y Y Li; P J Hu; C Manan; L Lesmana; R E Carpio; J Y Perez; K M Fock; U Kachintorn; K Phornphutkul; P Kullavanijaya; J Ho; S K Lam Journal: Aliment Pharmacol Ther Date: 2000-02 Impact factor: 8.171
Authors: T Furuta; N Shirai; M Takashima; F Xiao; H Hanai; H Sugimura; K Ohashi; T Ishizaki; E Kaneko Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875
Authors: H Schwartz; R Krause; B Sahba; M Haber; A Weissfeld; P Rose; N Siepman; J Freston Journal: Am J Gastroenterol Date: 1998-04 Impact factor: 10.864
Authors: E Bayerdörffer; S Miehlke; G A Mannes; A Sommer; W Höchter; J Weingart; W Heldwein; H Klann; T Simon; W Schmitt Journal: Gastroenterology Date: 1995-05 Impact factor: 22.682
Authors: I Thung; H Aramin; V Vavinskaya; S Gupta; J Y Park; S E Crowe; M A Valasek Journal: Aliment Pharmacol Ther Date: 2015-12-23 Impact factor: 8.171